REGN Regeneron (REGN) Q2 FY26 earnings call
Regeneron delivered a robust second quarter, driven by strong commercial execution across its key franchises, particularly Dupixent, EYLEA HD, and Libtayo. The company is actively pursuing further collaborations with Sanofi for next-generation programs and is focused on advancing its broad and diverse pipeline, including anticipated regulatory decisions for cemdisiran and garituzumab, and progressing its obesity and Factor XI programs. Management remains disciplined in capital allocation, prioritizing internal science while evaluating external opportunities.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
REGN operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | This call Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Patients DUPIXENT | 1.4M+DUPIXENT is currently the most widely used innovative branded antibody medicine with more than 1.4 million patients on therapy globally.Source: earnings call transcript | 1.4M+Turning to DUPIXENT, which continues to transform the lives of more than 1.4 million patients worldwide with type 2 inflammatory diseases that are currently on treatment.Source: earnings call transcript | 1.5M+Turning to Dupixen, which continues to deliver significant patient benefit to patients globally with more than 1.5 million patients actively treated worldwide, Dupixen has had a tremendous impact across these 9 approved indications, and it is the #1 biologic medicine prescribed by dermatologists and pulmonologist, allergists and ENTs, Second quarter net sales were $6 billion, reflects 38% growth on a constant currency basis and the US, sales grew 42% year-over-year to $4.6 billion, primarily driven by continued growth across our blockbuster indications and uptake in recent launches.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.